Active ingredientCilnidipineCat. No. P-C162-001CAS 132203-70-4Family · Pharmaceutical analytical standards
Cilnidipine
A dihydropyridine calcium channel blocker developed in Japan, patented in 1984 and approved for medical use in 1995 against high blood pressure; it has received approval in Japan, China, India, Korea and Nepal. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?Unlike most calcium channel blockers, it blocks not only the L-type calcium channels of blood vessels but also the N-type channels of nerve endings: in a clinical study it lowered not only blood pressure but also pulse rate.
Go to the active ingredient →Active ingredientCilnidipineCat. No. P-C162-001CAS 132203-70-4
Isotopically labelledCilnidipine-d3Cat. No. P-C162-002CAS 2714484-05-4
Isotopically labelledCilnidipine-d7Cat. No. P-C162-003
Impurity(E)-Dehydro CilnidipineCat. No. P-C162-004CAS 146845-34-3
Impurity(Z)-Dehydro CilnidipineCat. No. P-C162-005CAS 146845-35-4
ImpurityCilnidipine Impurity 2Cat. No. P-C162-007
ImpurityCilnidipine Impurity 3Cat. No. P-C162-008CAS 123853-41-8
ImpurityCilnidipine Impurity 4Cat. No. P-C162-009CAS 74936-76-8
ImpurityCilnidipine Impurity 5Cat. No. P-C162-010
ImpurityCilnidipine Impurity 6Cat. No. P-C162-011CAS 68077-28-1
ImpurityTriethyl aconitateCat. No. P-C162-012CAS 5349-99-5
ImpurityZ-CilnidipineCat. No. P-C162-013CAS 146924-45-0No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.